- Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.
Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.
Neuron (2013-01-29)
Emily K Osterweil, Shih-Chieh Chuang, Alexander A Chubykin, Michael Sidorov, Riccardo Bianchi, Robert K S Wong, Mark F Bear
PMID23352161
ABSTRACT
Many neuropsychiatric symptoms of fragile X syndrome (FXS) are believed to be a consequence of altered regulation of protein synthesis at synapses. We discovered that lovastatin, a drug that is widely prescribed for the treatment of high cholesterol, can correct excess hippocampal protein synthesis in the mouse model of FXS and can prevent one of the robust functional consequences of increased protein synthesis in FXS, epileptogenesis. These data suggest that lovastatin is potentially disease modifying and could be a viable prophylactic treatment for epileptogenesis in FXS.
MATERIALS
Product Number
Brand
Product Description
Lovastatin for peak identification, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Lovastatin, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
SKU
Pack Size
Availability
Price
Quantity